89 active not recruiting. 89 Phase 3, 21 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 89 | Active not recruiting 89 |
| Phase 2 | 21 | Active not recruiting 21 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome TSHA-102 - Rett Syndrome | Phase 3 | Active not recruiting | Taysha Gene Therapies, Inc. | 4 | 2026-05-08 | 2026-08-19 |
| A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy TAK-861, Placebo - Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy | Phase 3 | Active not recruiting | Takeda | 98 | 2026-01-29 | 2026-10-30 |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease Trontinemab, Placebo - Alzheimers Disease | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1060 | 2025-11-12 | 2026-09-25 |
| An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) Azetukalner - Bipolar Depression, Bipolar I Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 400 | 2025-10-30 | 2026-10-13 |
| Study on the Efficacy and Safety of QLM1016 in Schizophrenia 3-6mg QLM1016, 10-20 mg Aripiprazole oral solution film - Schizophrenia | Phase 3 | Active not recruiting | Qilu Pharmaceutical Co., Ltd. | 402 | 2025-10-02 | 2026-10-14 |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder VQW-765, Placebo - Social Anxiety Disorder (SAD) | Phase 3 | Active not recruiting | Vanda Pharmaceuticals | 500 | 2025-09-22 | 2026-08-17 |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease Trontinemab, Placebo - Alzheimers Disease | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1101 | 2025-09-17 | 2026-09-25 |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) Azetukalner, Placebo - Bipolar Disorder, Bipolar Depression | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 400 | 2025-08-08 | 2026-10-13 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2025-07-08 | 2026-10-15 |
| Telemedicine XR-B for Individuals in Jail Extended Release Buprenorphine - Opioid Use Disorder | Phase 3 | Active not recruiting | Friends Research Institute, Inc. | 30 | 2025-06-01 | 2026-04-24 |
| Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease SKY-0515, SKY-0515 Placebo - Huntington Disease, Huntingtons Disease | Phase 2 / Phase 3 | Active not recruiting | Skyhawk Therapeutics, Inc. | 120 | 2025-05-27 | 2026-05-01 |
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) Placebo, DT120 - Major Depressive Disorder | Phase 3 | Active not recruiting | Definium Therapeutics US, Inc. | 149 | 2025-04-14 | 2026-08-28 |
| An Open-Label Study of Azetukalner in Major Depressive Disorder Azetukalner - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 460 | 2025-03-18 | 2026-10-13 |
| A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia SEP-363856, Placebo - Schizophrenia | Phase 3 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 538 | 2025-02-28 | 2026-10-05 |
| Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance. Turmeric extract, Control: Placebo. 500mg gelatin in capsules 2 times a day - Cognitive Decline, Subjective Cognitive Impairment | Phase 2 / Phase 3 | Active not recruiting | Instituto Mexicano del Seguro Social | 100 | 2025-02-20 | 2026-03-25 |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD buntanetap/posiphen, Placebo - Early Alzheimers Disease | Phase 3 | Active not recruiting | Annovis Bio Inc. | 760 | 2025-02-04 | 2026-05-18 |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) Placebo, DT120 - Generalized Anxiety Disorder | Phase 3 | Active not recruiting | Definium Therapeutics US, Inc. | 245 | 2025-01-29 | 2026-09-04 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Azetukalner, Placebo - Major Depressive Disorder | Phase 3 | Active not recruiting | Xenon Pharmaceuticals Inc. | 450 | 2024-12-20 | 2026-10-13 |
| A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) Placebo, DT120 - Generalized Anxiety Disorder | Phase 3 | Active not recruiting | Definium Therapeutics US, Inc. | 214 | 2024-12-11 | 2026-09-25 |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) LP352, Placebo - Developmental and Epileptic Encephalopathy | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 367 | 2024-11-11 | 2026-09-15 |
Showing 20 of 89. Sign in to see all of them.
Alzheimer Disease (17) · Cognitive Dysfunction (12) · Dementia (11) · Depression (9) · Depressive Disorder, Major (8) · Nervous System Diseases (7) · Anxiety Disorders (6) · Neurodevelopmental Disorders (6) · Opioid-Related Disorders (6) · Bipolar Disorder (4) · Genetic Diseases, X-Linked (4) · Intellectual Disability (4) · Neurologic Manifestations (4) · Stress Disorders, Post-Traumatic (4)
Nervous System Diseases (33) · Neurocognitive Disorders (27) · Pathological Conditions, Signs and Symptoms (25) · Central Nervous System Diseases (24) · Brain Diseases (23) · Behavior (20) · Signs and Symptoms (19) · Neurodegenerative Diseases (18) · Mood Disorders (16) · Tauopathies (16) · Behavioral Symptoms (15) · Cognition Disorders (13) · Depressive Disorder (13) · Dementia (12)
donanemab (4) · lecanemab (4) · Cognitive Behavioral Therapy (3) · Psilocybin (3) · XEN1101 (3) · Fluoxetine (2) · Haloperidol (2) · Midazolam (2) · Antidepressive Agents (1) · Antipsychotic Agents (1) · Cannabidiol (1) · Capsules (1) · Chlorhexidine (1) · Chlorpromazine (1) · Cognitive Training (1)
Eli Lilly and Company (5) · M.D. Anderson Cancer Center (5) · Xenon Pharmaceuticals Inc. (5) · Definium Therapeutics US, Inc. (3) · Friends Research Institute, Inc. (3) · Washington University School of Medicine (3) · Cook MyoSite (2) · Hoffmann-La Roche (2) · Longboard Pharmaceuticals (2) · Taysha Gene Therapies, Inc. (2) · Vanderbilt University Medical Center (2) · AO GENERIUM (1) · Abdallah Mohamed Abdallah Mohamed Elgendy (1) · Abraham Nunes (1) · Abramson Cancer Center at Penn Medicine (1)
United States (71) · United Kingdom (17) · Australia (16) · Canada (16) · Spain (15) · Germany (13) · Japan (13) · France (11) · China (10) · Italy (10) · Poland (10) · Netherlands (8) · Brazil (7) · Argentina (5) · Puerto Rico (5)
Randall J Bateman, MD (3) · David Hui (2) · Abdelraouf Elmohsen, Professor (1) · Abraham Nunes, MD PhD MBA FRCPC (1) · Ahmed Elshahid, Professor (1) · Amy E Brown, MD (1) · Ban Leong Sng, FANZCA (1) · Bradley S. Peterson, MD (1) · Cecilia Bergeria, PhD (1) · Charles Raison, MD (1) · Christopher P Cardozo, MD (1)
PMID 42552749, PMID 38723617, PMID 41730563, PMID 18974308, PMID 24565357, PMID 25486372, PMID 25721183, PMID 28384010, PMID 31587995, PMID 32479786, PMID 34193105, PMID 36341846, PMID 36449413, PMID 36934371, PMID 37009976, PMID 37017737, PMID 37203336, PMID 37459141, PMID 37491196, PMID 37990597, PMID 38032645, PMID 38254921, PMID 38323738, PMID 38581616, PMID 38730496, PMID 38940656, PMID 39292433, PMID 39434728, PMID 39575854, PMID 39732915, PMID 39804360, PMID 39974075, PMID 40034530, PMID 40042496, PMID 40063015, PMID 40113655, PMID 40120616, PMID 40133524, PMID 40172303, PMID 40173263, PMID 40342086, PMID 40470239, PMID 40603145, PMID 40619285, PMID 40667684, PMID 40673228, PMID 40739549, PMID 40742738, PMID 40802027, PMID 40935422
R01AG046179 (2), R01AG053267 (2), R56AG053267 (2), U01AG042791 (2), U01AG059798 (2), 1IK2CX001774-01 (1), 2018 (1), 2023 (1), 2025 (1), R01AG052510 (1), R01AG062624 (1), R01AG068319 (1), R01AG070349 (1), R01AG076518 (1), R01CA243914 (1)